TBI Therapy and Neurodegenerative Diseases Therapy: Addressing the Unmet Medical Need

Diminished blood flow to the brain caused by conditions such as thrombosis, embolism, cardiac arrest, or injury can give rise to focal or global cerebral ischemia. This ischemic state induces changes in brain metabolism, a decrease in metabolic rates, and eventual neuronal death. Importantly, ischemia can lead to irreversible consequences. Current post-injury interventions aimed at mitigating cell death resulting from acute ischemic stroke are limited.

To date, no drug has been approved worldwide for TBI therapy.  Recognizing the existing gap in medical solutions, there is a pressing need for the development of innovative drugs for traumatic brain injury (TBI) therapy. 

Neurodegenerative diseases pose significant challenges to patients, caregivers, and healthcare systems worldwide. Despite extensive research efforts, there remains a pressing need for effective treatments that can halt or slow disease progression, alleviate symptoms, and improve quality of life for affected individuals. Many existing therapies only provide symptomatic relief and do not address the underlying mechanisms driving neurodegeneration.

Our focus is on pioneering gene therapy and cutting-edge technology for systemic delivery of the drug to CNS by passing through blood-brain barrier as a promising approach to address TBI and neurodegenerative diseases.

Cancer Therapy: Meeting the Growing Demand

The rising incidence of cancer cases underscores the imperative for advanced cancer therapies to effectively treat patients. Our commitment to this challenge involves the development of innovative drugs across various modalities, including protein engineering, immunotherapy, gene therapy, cell therapy, and small molecules. These efforts are aimed at addressing both solid tumors and hematological malignancies, reflecting our dedication to advancing comprehensive solutions in the field of cancer treatment.

Advancing Drug Development for Improved Organ Transplantation Survival

Organ transplantation encounters numerous challenges, with immune rejection standing out as a primary obstacle leading to transplant failure. In response to this critical issue, we are actively engaged in the development of groundbreaking drugs designed to modulate the immune system. Our goal is to effectively attenuate immune rejection, thereby enhancing the overall success and longevity of organ transplants.

Drug Development for Therapy Targeting Autoimmune Diseases 

The exact cause of autoimmune diseases is not fully understood, but they are believed to result from a combination of genetic, environmental, and immunological factors. Genetic predisposition plays a significant role, as certain genes can increase the risk of developing autoimmune diseases. Environmental factors such as infections, exposure to toxins, and dietary factors may also trigger or exacerbate autoimmune responses in susceptible individuals. Additionally, dysregulation of the immune system, including abnormalities in immune cell function and communication, contributes to the development of autoimmune diseases. 

We are committed to advancing the understanding and treatment of autoimmune diseases through innovative research, collaboration, and a dedication to improving patient outcomes. Stay tuned for updates on our latest advancements in this field.